CAMBRIDGE, Mass.--(BUSINESS WIRE)--FoldRx Pharmaceuticals, Inc. (FoldRx) today announced that enrollment is underway in an open-label Phase II clinical study with its lead drug candidate, Fx-1006A, for patients suffering from TTR Amyloid Cardiomyopathy (ATTR-CM). The company also announced progress in several other ongoing studies that are part of a larger development program evaluating its lead candidate. Fx-1006A is designed to stop the progression of TTR amyloidosis caused by the ‘misfolding’ of a protein called transthyretin (TTR) and the subsequent accumulation of amyloid fibrils in various tissues, such as the heart and peripheral nerve tissue, with resultant cardiomyopathy and neuropathy, respectively.
